Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
:
Nonetheless, the results provide reassuring evidence for clinicians and patients, supporting the continued use of GLP-1 receptor agonists in Type 2 diabetes without added concern for pancreatitis risk, and raising the possibility of improved outcomes in those who do develop the condition
G., Tantama, M
While the overall number of affected patients was small (0.2% versus 0.1%), the difference was statistically significant
What they found: Prevention of age-related changes in gene expression , NMN-treated mice had an expression profile closer to young mice Restoration of mitochondrial function in multiple tissues Improvement of insulin sensitivity of 35 to 50 % Preserved muscle strength and endurance Preserved bone density Better vision (NMN-treated mice had a slower decline in ophthalmologic parameters) No serious adverse effects Why it matters: This is the most ambitious preclinical study of NMN/NAD+ in animal aging models
Reduction of the tremor of Parkinson's disease
